Imatimib Mesylate
Phase 1Small molecule
Imatimib Mesylate is one of 13 small molecule programs targeting Lymphangioleiomyomatosis. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Lymphangioleiomyomatosis
#DrugCompanyPhaseTrials
1Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Proair HFA
GGlaxo Dba Glaxosmithkline
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
Afinitor
NovartisPhase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Femara
NovartisPhase 2
Aristan
NNational Cancer Institute (NCI)
Phase 2
Ofev
Boehringer IngelheimPhase 2
Sandostatin
Sun PharmaPhase 2
Claritin
PPerrigo Company
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphangioleiomyomatosis1 trial
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
Recruiting·—·Phase 1·NCT06889168·20 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Imatimib Mesylate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Pittsburgh